iDEL Therapeutics Partners with Daiichi Sankyo to Evaluate Novel Cancer Drug Delivery Platform
Key Points
- iDEL Therapeutics entered a multi-year research collaboration with Daiichi Sankyo to evaluate a multi-drug conjugate using its synthetic shuttle technology in solid tumors.
- The preclinical study will compare the candidate against an antibody-drug conjugate with a comparable payload and explore overcoming cellular uptake and endosomal entrapment.
- iDEL reports preclinical proof-of-concept with small molecules, peptides, and VHH antibody fragments, aiming to improve intracellular drug exposure and therapeutic windows.
iDEL Therapeutics has entered a multi-year research collaboration with Daiichi Sankyo to investigate a new approach to delivering combination cancer therapies directly into solid tumor cells. The agreement will focus on the preclinical evaluation of a multi-drug conjugate (MDC) developed using iDEL’s synthetic shuttle technology. Researchers from iDEL and Daiichi Sankyo’s Research Institute Munich will assess the candidate’s performance against an antibody-drug conjugate (ADC) carrying a comparable payload. The companies did not disclose financial terms or other details of the agreement. The collaboration will explore whether iDEL’s delivery platform can overcome limitations associated with cellular drug uptake and endosomal entrapment, which can prevent therapeutic compounds from reaching their intended intracellular targets.
“As one of the world leaders in the development of targeted cancer medicines and ADCs, Daiichi Sankyo is the ideal collaborator to support the research and future development of this novel MDC, enabled by iDEL’s synthetic shuttle technology,” says Marcus Kostka, PhD, co-founder and CEO of iDEL Therapeutics. He adds that the partnership provides an opportunity to demonstrate the broader potential of the company’s modular delivery platform.
iDEL is developing its technology to transport therapeutic payloads directly into the cytosol, with the goal of improving intracellular drug exposure and expanding access to targets that have historically been difficult to address with conventional therapies. The company reports preclinical proof-of-concept results using small molecules, peptides, and VHH antibody fragments against intracellular targets. Its pipeline includes both MDC and single-domain antibody programs targeting solid tumors.
Beyond the Daiichi Sankyo collaboration, iDEL plans to continue advancing its delivery platform with the aim of improving therapeutic windows and expanding treatment options for cancer patients.
Find more information at www.idel-tx.com
Total Page Views: 8
